Cargando…
Monotherapy in patients with type 2 diabetes mellitus
In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668404/ https://www.ncbi.nlm.nih.gov/pubmed/29057643 http://dx.doi.org/10.3904/kjim.2017.312 |
_version_ | 1783275668485701632 |
---|---|
author | Rhee, Sang Youl Kim, Hyun Jin Ko, Seung-Hyun Hur, Kyu Yeon Kim, Nan-Hee Moon, Min Kyong Park, Seok-O Lee, Byung-Wan Choi, Kyung Mook Kim, Jin Hwa |
author_facet | Rhee, Sang Youl Kim, Hyun Jin Ko, Seung-Hyun Hur, Kyu Yeon Kim, Nan-Hee Moon, Min Kyong Park, Seok-O Lee, Byung-Wan Choi, Kyung Mook Kim, Jin Hwa |
author_sort | Rhee, Sang Youl |
collection | PubMed |
description | In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly. |
format | Online Article Text |
id | pubmed-5668404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-56684042017-11-13 Monotherapy in patients with type 2 diabetes mellitus Rhee, Sang Youl Kim, Hyun Jin Ko, Seung-Hyun Hur, Kyu Yeon Kim, Nan-Hee Moon, Min Kyong Park, Seok-O Lee, Byung-Wan Choi, Kyung Mook Kim, Jin Hwa Korean J Intern Med Review In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by monotherapy, a combination therapy with different mechanisms of action should be initiated promptly. The Korean Association of Internal Medicine 2017-11 2017-10-23 /pmc/articles/PMC5668404/ /pubmed/29057643 http://dx.doi.org/10.3904/kjim.2017.312 Text en Copyright © 2017 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Rhee, Sang Youl Kim, Hyun Jin Ko, Seung-Hyun Hur, Kyu Yeon Kim, Nan-Hee Moon, Min Kyong Park, Seok-O Lee, Byung-Wan Choi, Kyung Mook Kim, Jin Hwa Monotherapy in patients with type 2 diabetes mellitus |
title | Monotherapy in patients with type 2 diabetes mellitus |
title_full | Monotherapy in patients with type 2 diabetes mellitus |
title_fullStr | Monotherapy in patients with type 2 diabetes mellitus |
title_full_unstemmed | Monotherapy in patients with type 2 diabetes mellitus |
title_short | Monotherapy in patients with type 2 diabetes mellitus |
title_sort | monotherapy in patients with type 2 diabetes mellitus |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668404/ https://www.ncbi.nlm.nih.gov/pubmed/29057643 http://dx.doi.org/10.3904/kjim.2017.312 |
work_keys_str_mv | AT rheesangyoul monotherapyinpatientswithtype2diabetesmellitus AT kimhyunjin monotherapyinpatientswithtype2diabetesmellitus AT koseunghyun monotherapyinpatientswithtype2diabetesmellitus AT hurkyuyeon monotherapyinpatientswithtype2diabetesmellitus AT kimnanhee monotherapyinpatientswithtype2diabetesmellitus AT moonminkyong monotherapyinpatientswithtype2diabetesmellitus AT parkseoko monotherapyinpatientswithtype2diabetesmellitus AT leebyungwan monotherapyinpatientswithtype2diabetesmellitus AT choikyungmook monotherapyinpatientswithtype2diabetesmellitus AT kimjinhwa monotherapyinpatientswithtype2diabetesmellitus AT monotherapyinpatientswithtype2diabetesmellitus |